EC
FLNA

EntryPoint Capital’s Filana Therapeutics FLNA Stock Holding History

EntryPoint Capital’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,297
Closed -$46.6K – 1534
2024
Q1 		$46.6K Buy
2,297
+2,127
+1,251% +$49K 0.04% 800
2023
Q4 		$3.83K Buy
+170
New +$3.59K ﹤0.01% 1240

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

EntryPoint Capital's FLNA Position: Q2 2024 in Review

EntryPoint Capital sold out of Filana Therapeutics (FLNA) in Q2 2024, closing a stake of 2,297 shares — an estimated $46.6K sold.

EntryPoint Capital first reported a position in FLNA in Q4 2023 and held it in 2 quarters. The position peaked at $46.6K in Q1 2024. 145 funds tracked by Wall St. Rank hold FLNA as of Q2 2024.

  • EntryPoint Capital reported no remaining Filana Therapeutics position as of Q2 2024 after selling out during the quarter.
  • EntryPoint Capital sold 2,297 Filana Therapeutics shares in Q2 2024, an estimated $46.6K.
  • EntryPoint Capital first reported a position in Filana Therapeutics in Q4 2023 and held it in 2 quarters.
  • EntryPoint Capital's Filana Therapeutics position peaked at $46.6K in Q1 2024.
  • 145 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.